A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study

NCT04814069 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer
Radiation
PD-1

Interventions

DRUG: Tislelizumab

Sponsor

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University